These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1988217)

  • 1. Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcillin, and sulfamethoxazole.
    Dasgupta A; Dennen DA; Dean R; McLawhon RW
    Clin Chem; 1991 Jan; 37(1):98-100. PubMed ID: 1988217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of serum albumin on in vitro displacement of valproic acid by ceftriaxone and nafcillin.
    Dasgupta A; Dennen DA; Dean R
    Clin Chem; 1990 May; 36(5):825-6. PubMed ID: 2110875
    [No Abstract]   [Full Text] [Related]  

  • 3. Phenytoin-oxacillin interactions in normal and uremic sera.
    Dasgupta A; Sperelakis A; Mason A; Dean R
    Pharmacotherapy; 1997; 17(2):375-8. PubMed ID: 9085332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera.
    Dasgupta A; Timmerman TG
    Ther Drug Monit; 1996 Feb; 18(1):97-9. PubMed ID: 8848829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam.
    McNamara PJ; Trueb V; Stoeckel K
    Biochem Pharmacol; 1990 Sep; 40(6):1247-53. PubMed ID: 2403378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
    Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia.
    Dager WE; Inciardi JF; Howe TL
    Ann Pharmacother; 1995; 29(7-8):667-70. PubMed ID: 8520077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased plasma protein binding of phenytoin in patients on valproic acid.
    Dahlqvist R; Borgå O; Rane A; Walsh Z; Sjöqvist F
    Br J Clin Pharmacol; 1979 Dec; 8(6):547-52. PubMed ID: 391256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of free phenytoin to serum albumin in cancer patients.
    Umstead GS; Neumann KH
    DICP; 1990 Oct; 24(10):923-6. PubMed ID: 2244404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Displacement effect of ceftriaxone on bilirubin bound to human serum albumin.
    Gulian JM; Dalmasso C; Pontier F; Gonard V
    Chemotherapy; 1986; 32(5):399-403. PubMed ID: 3757585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein binding of digitoxin, valproate and phenytoin in sera from diabetics.
    Doucet J; Fresel J; Hue G; Moore N
    Eur J Clin Pharmacol; 1993; 45(6):577-9. PubMed ID: 8157046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A graphical nomogram method for predicting toxic concentrations of unbound phenytoin.
    Pospisil J; Pelclová D
    Int J Clin Pharmacol Ther; 1994 Mar; 32(3):122-5. PubMed ID: 8205372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid: in vitro plasma protein binding and interaction with phenytoin.
    Cramer JA; Mattson RH
    Ther Drug Monit; 1979; 1(1):105-16. PubMed ID: 121944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma protein binding interaction between phenytoin and valproic acid in vitro.
    Monks A; Boobis S; Wadsworth J; Richens A
    Br J Clin Pharmacol; 1978 Dec; 6(6):487-92. PubMed ID: 365209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of valproate on free plasma phenytoin concentrations.
    Tsanaclis LM; Allen J; Perucca E; Routledge PA; Richens A
    Br J Clin Pharmacol; 1984 Jul; 18(1):17-20. PubMed ID: 6430316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin.
    Dasgupta A; Crossey MJ
    Am J Med Sci; 1997 Feb; 313(2):75-9. PubMed ID: 9030671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats.
    Chou RC; Levy G
    J Pharmacol Exp Ther; 1981 Oct; 219(1):42-8. PubMed ID: 7288614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration.
    Johnson GJ; Kilpatrick CJ; Bury RW; Fullinfaw RO; Moulds RF
    Br J Clin Pharmacol; 1989 Jun; 27(6):843-9. PubMed ID: 2503019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds.
    Dasgupta A; Abu-Alfa A
    Am J Clin Pathol; 1992 Jul; 98(1):19-25. PubMed ID: 1615921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.